SiBone (NASDAQ:SIBN) SVP Sells $54,511.38 in Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 3,726 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $14.63, for a total transaction of $54,511.38. Following the transaction, the senior vice president directly owned 280,509 shares of the company’s stock, valued at $4,103,846.67. This trade represents a 1.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SiBone Stock Down 0.9%

SIBN opened at $14.68 on Friday. The firm has a 50-day simple moving average of $13.39 and a two-hundred day simple moving average of $16.09. The company has a quick ratio of 8.34, a current ratio of 9.99 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $651.06 million, a PE ratio of -37.64 and a beta of 0.67. SiBone has a 52 week low of $11.48 and a 52 week high of $21.89.

SiBone (NASDAQ:SIBN) last announced its earnings results on Monday, May 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.07. The firm had revenue of $52.59 million for the quarter, compared to analysts’ expectations of $51.16 million. SiBone had a negative net margin of 8.10% and a negative return on equity of 9.56%. Analysts forecast that SiBone will post -0.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

SIBN has been the topic of several recent research reports. Wall Street Zen cut shares of SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. TD Cowen decreased their target price on shares of SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Finally, Truist Financial restated a “buy” rating and set a $18.00 target price (down from $20.00) on shares of SiBone in a research report on Tuesday, May 12th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, SiBone presently has an average rating of “Moderate Buy” and an average price target of $23.00.

Hedge Funds Weigh In On SiBone

A number of institutional investors have recently modified their holdings of SIBN. ANTIPODES PARTNERS Ltd purchased a new position in shares of SiBone during the fourth quarter worth approximately $29,000. Royal Bank of Canada increased its position in shares of SiBone by 98.5% during the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after acquiring an additional 736 shares during the period. Caitong International Asset Management Co. Ltd increased its position in shares of SiBone by 64,700.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock worth $38,000 after acquiring an additional 1,941 shares during the period. State of Alaska Department of Revenue purchased a new position in shares of SiBone during the third quarter worth approximately $39,000. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of SiBone during the fourth quarter worth approximately $53,000. 98.11% of the stock is owned by hedge funds and other institutional investors.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.